On this page

The early period

An early postoperative event and a stroke years later are different outcomes. Japanese guidance discusses ischemic complications and hyperperfusion, where blood flow after revascularization may be excessive for the affected tissue. New neurological symptoms require clinical assessment to distinguish possible causes.1

When reading a complication rate, check its time window and whether it counts people or operated hemispheres. A study ending shortly after surgery measures a different period from a long-term stroke-prevention study. Neither figure should silently replace the other.

Later outcomes answer different questions

JAM's recurrent-bleeding endpoint concerns adults after hemorrhage. It does not measure universal freedom from all symptoms or recovery of cognition. Its randomized design is valuable within its scope, with small-sample uncertainty still relevant.2

The pediatric long-term series reports stroke, independence and vascular imaging separately. A patent vessel does not itself tell the reader whether learning, daily function or quality of life improved. The series has no untreated comparator, and the available observations differ by outcome.3

Asymptomatic does not mean an established absence of future risk. In AMORE, strokes occurred during five-year observation of selected adults. This is natural-history evidence, not a comparison proving preventive surgery benefits every asymptomatic patient.4

Life expectancy and cure questions

A search for “moyamoya disease life expectancy” is understandable, but these sources do not provide a single number that predicts an individual's lifespan. A selected surgical series and an asymptomatic adult registry describe different populations and follow-up periods. Applying either to everyone would lose the clinical context.

Discuss prognosis in terms of the actual diagnosis, presentation, previous injury, proposed treatment and outcomes important to you. Ask what is known, what remains uncertain and which future findings could change the care plan. A favorable scan should not be translated into a guarantee about cognition or independence.

What to clarify at follow-up

ESO supports continuing neuroimaging assessment through expert consensus, including attention to progression and initially unilateral disease. It leaves timing individualized.5

Ask the team what each follow-up visit will examine: further events, symptoms, function, collateral development or progression elsewhere. Clarify who arranges the next assessment and how results will be explained. If learning, memory or daily activities are concerns, raise them explicitly rather than treating imaging as the complete outcome.

Keep the written plan and reports available to the team responsible for care. For sudden weakness, speech or vision changes, imbalance or unexplained severe headache, call local emergency services immediately; resolving symptoms still need urgent assessment. A scheduled follow-up visit is not the response to a possible acute stroke.6

References

  1. Fujimura M et al. Neurologia medico-chirurgica. 2022;62:165–170. doi:10.2176/jns-nmc.2021-0382. Source ↩
  2. Miyamoto S et al. Stroke. 2014;45:1415–1421. doi:10.1161/STROKEAHA.113.004386. PubMed ↩
  3. Riordan CP et al. Journal of Neurosurgery: Pediatrics. 2019;23:586–592. doi:10.3171/2019.1.PEDS18457. PubMed ↩
  4. Kuroda S et al. Stroke. 2023;54:1494–1504. doi:10.1161/STROKEAHA.122.041932. PubMed ↩
  5. Bersano A et al. European Stroke Journal. 2023;8:55–84. doi:10.1177/23969873221144089. Corrected March 2023. Source ↩
  6. US Centers for Disease Control and Prevention. Signs and Symptoms of Stroke. 19 May 2026. Source ↩